ERBB2 and endometrial cancer: An ongoing prospective multicenter study called Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC) is currently accruing patients in Europe to investigate the predictive value of p53, p16, estrogen receptor, progesterone receptor and HER2/neu markers.